Johannes Karges develops anti-cancer agents that work in a targeted manner, rather than adversely affecting the entire body.
The Delisting Risk
You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight